Imaging Endpoints Appoints Brian Kelly as Vice President, Business Development and Marketing


SCOTTSDALE, Ariz., October 10, 2022 /PRNewswire/ — Imaging Endpoints (IE), the world’s largest specialized oncology imaging CRO, today announced the addition of Brian Kelly as Vice President, Business Development and Marketing. In this role, Brian will be responsible for the continued growth of IE’s imaging CRO business.

Prior to joining Imaging Endpoints, Brian held global business development and marketing positions at several companies supporting endpoint imaging for clinical trials. Brian’s most recent experience includes over 11 years at AG Mednet where he led global sales and built the company into the leader in clinical trial image management. Prior to AG Mednet, Brian oversaw global sales and marketing for SYNARC (now Clario), previously the industry’s largest central imaging lab.

“Brian is an ideal addition to our leadership team, bringing over 20 years of experience in medical imaging in support of clinical trials,” said Imaging Endpoints COO. Jatinder Kaur. “Many of our customers and partners already know Brian, and all will be delighted with his willingness to continue to build long-term relationships based on science and service excellence.”

“I couldn’t be more excited to join the amazing team at Imaging Endpoints,” said Brian Kelly, vice president of business development and marketing. “I look forward to helping our team Connect imaging to the Cure™ and support our dedicated colleagues in the biopharmaceutical industry as they seek better therapies for us all. »

Brian holds a BS and MBA in Marketing from Bryant University.

About Imaging Endpoints

Imaging Endpoints (IE) is passionately dedicated to its vision of “Connect Imaging to the Cure” and works every day to advance imaging science, technology and services aimed at bringing healing technologies to humanity.

Having supported the approval of many of the most impactful new drugs in oncology, IE’s experience encompasses imaging customization to facilitate regulatory approval in hundreds of trials across all phases of development. IE also provides data to support trial efficiency by integrating advanced imaging technologies such as CD8 imaging, tumor growth kinetics, radiomics and artificial intelligence – areas in which over 50 publications assessed peer review established IE as the industry leader.

IE is headquartered in Scottsdale, AZwith offices at Cambridge, MA; London, United Kingdom; Leiden, Netherlands; Basel, Switzerland; Hyderabad, Indiaand Shanghai, China. The company is a subsidiary of HonorHealth, one of the nation’s largest health systems, and is also a subsidiary of Southwest Medical Imaging, Ltd. (SMIL/RadPartners), which is part of the largest private radiology group in the United States.

Samuel Lofland
[email protected]

SOURCE Imaging Endpoints


Comments are closed.